Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes, according to new research being presented at the European Congress on Obesity (ECO) in Malaga, Spain (11–14 May).
This article was originally published on MedicalXpress.com